- Humana continues to project an adjusted EPS for the fiscal year at approximately $17, in alignment with estimates standing at $17.02.
- The company maintains its EPS expectation of about $13.77, contrasting slightly with the estimates of $15.11.
- Commentary on the 2026 Medicare Advantage star ratings will be withheld by Humana until the Centers for Medicare & Medicaid Services (CMS) releases the final data in October.
- Current investor sentiment shows 9 buy, 18 hold, and 0 sell recommendations for Humana’s stock.
A look at Humana Inc Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 2 | |
| Growth | 3 | |
| Resilience | 3 | |
| Momentum | 5 | |
| OVERALL SMART SCORE | 3.2 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Humana Inc, a managed health care company operating in the United States and Puerto Rico, shows a promising long-term outlook according to Smartkarma Smart Scores. With a solid Momentum score of 5, indicating strong positive market trend, Humana appears to be performing exceptionally well in this aspect. Additionally, the company scores fairly across other factors including Value, Growth, and Resilience, with scores of 3 across the board. This balanced performance suggests stability coupled with growth potential for Humana in the foreseeable future.
Overall, Humana Inc‘s Smartkarma Smart Scores reflect a company that is well-positioned in the healthcare industry. The company’s strategic focus on coordinated health care services through various plans and products caters to a diverse range of clients, including employer groups, government-sponsored plans, and individual consumers. With consistent scores across different categories, Humana seems primed for steady growth and continued success in the long run.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
